|
Media Releases |
Financial Reports |
Presen-tations |
|
06/26/2007
|
|
|
|
| Lonza launches PyroSense® system for on-line endotoxin detection in water systems. |
Basel, 26.06.2007 – Lonza, the global life sciences company, announces the launch of the PyroSense® on-line monitoring system for the automatic detection of endotoxin in water systems.
The PyroSense® system provides automatic, quantitative determination of endotoxin in water at user selected intervals, using a standard assay system with our patented endotoxin-specific PyroGene® recombinant Factor C assay. The system is designed to test around the clock, seven days a week according to user demand. The system is designed to operate in production environments with minimal supervision. All the reagents and accessories are provided in a disposable cartridge that can be quickly and easily changed by non-technical personnel or by production or quality control (QC) staff.
Water testing represents approximately 50% or more of the current average volume of testing in the QC laboratory. The PyroSense® system offers a cost-effective solution for early identification of potential contamination in your water system, reducing overall testing costs and reducing risk. Contact your local representative or visit www.lonzabioscience.com/lal for more details today.
Developed to meet the growing need for better control of water quality for production purposes, the PyroSense® system facilitates as well the move towards direct on-line monitoring of raw or in-process materials, in line with the FDA and EMEA Process Analytical Technology (PAT) Initiatives.
About Lonza
Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of pharmaceutical active ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also a leading provider of value added chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2006 Lonza had sales of CHF 2.91 billion. Further information can be found at www.lonza.com.
For further information:
Investor / Media Relations Lonza
Margot Connor
Tel +41 61 316 8566
Fax +41 61 316 9566
margot.connor@lonza.com
Media Relations Lonza German
Dominik Werner
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com
Investor Relations Lonza
Alexandre Pasini
Tel +41 61 316 8835
Fax +41 61 316 9835
alexandre.pasini@lonza.com
|
|
|
